AT-527 has a unique mechanism of action, with dual targets including chain termination (RdRp) and NiRAN inhibition, which has the potential to create a high barrier to resistance.
For the treatment of COVID-19, we need transformational solutions, and we believe that oral, safe, direct-acting antivirals can play an essential role worldwide. The value and global health impact of a direct-acting antiviral is to rapidly inhibit viral replication in the early phase of infection, which has the effect of reducing disease progression and curtailing the spread of infection.
While vaccines will play an important role in mitigating the COVID-19 pandemic, we will need treatment options to stay ahead of the virus. To treat patients who are waiting to or do not want to be immunized and for patients for whom the vaccine does not create protective immunity, direct-acting antivirals are and will remain an essential complement to vaccines.
AT-527 is being evaluated for easy and early administration to reduce burden and duration of disease. AT-527 has the potential to be used for pre- and post-exposure prophylaxis, to reduce transmission and to impact long-term COVID sequelae.
Complementary medical intervention to vaccination similar to the influenza paradigm (Tamiflu®)
Significant advantages vs antibodies:
Highly-conserved target has potential to enable antiviral activity in the presence of multiple variants
Antiviral activity against potential future coronaviruses beyond SARS-CoV-2 anticipated
Generally safe and well tolerated (no drug related SAEs or discontinuations) in studies being conducted for the treatment of COVID-19 and studies conducted in HCV.
High solubility promotes rapid absorption.
Designed for QD or BID (twice daily) oral administration.
Efficient and scalable manufacture of drug product.
To learn more about our current clinical trials evaluating AT-527 for the treatment of coronavirus disease (COVID-19), please use the links below: